Identification

Name
Ticagrelor
Accession Number
DB08816  (DB04902)
Type
Small Molecule
Groups
Approved
Description

Ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. Unlike clopidogrel, ticagrelor is not a prodrug and does not require metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011.

Structure
Thumb
Synonyms
  • (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-D)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
External IDs
AR-C126532XX / AZD 6140 / AZD-6140 / AZD6140
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BrilintaTablet90 mg/1Oralbryant ranch prepack2011-08-052018-05-31Us
BrilintaTablet60 mg/1OralAstra Zeneca Lp2015-09-04Not applicableUs
BrilintaTablet60 mgOralAstra Zeneca2016-06-13Not applicableCanada
BrilintaTablet90 mg/1OralCardinal Health2011-08-05Not applicableUs
BrilintaTablet90 mgOralAstra Zeneca2011-06-01Not applicableCanada
BrilintaTablet90 mg/1OralAstra Zeneca Lp2011-08-05Not applicableUs00186 0777 60 nlmimage10 8639c32e
BriliqueTablet, film coated60 mgOralAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueTablet, film coated90 mgOralAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueTablet, film coated90 mgOralAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueTablet, film coated60 mgOralAstra Zeneca Ab2010-12-03Not applicableEu
International/Other Brands
Brilique (AstraZeneca) / Possia (AstraZeneca)
Categories
UNII
GLH0314RVC
CAS number
274693-27-5
Weight
Average: 522.568
Monoisotopic: 522.186080514
Chemical Formula
C23H28F2N6O4S
InChI Key
OEKWJQXRCDYSHL-FNOIDJSQSA-N
InChI
InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
IUPAC Name
(1S,2S,3R,5S)-3-(7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
SMILES
CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1

Pharmacology

Indication

For the prevention of thrombotic events (for example stroke or heart attack) in patients with acute coronary syndrome or myocardial infarction with ST elevation.

Associated Conditions
Pharmacodynamics

Plasma concentrations of ticagrelor are slightly increased (12–23%) in elderly patients, women, patients of Asian ethnicity, and patients with mild hepatic impairment. They are decreased in patients that described themselves as 'coloured' and such with severe renal impairment. These differences are considered clinically irrelevant. In Japanese people, concentrations are 40% higher than in Caucasians, or 20% after body weight correction. The drug has not been tested in patients with severe hepatic impairment.

Mechanism of action

Like the thienopyridines prasugrel, clopidogrel and ticlopidine, ticagrelor blocks adenosine diphosphate (ADP) receptors of subtype P2Y12. In contrast to the other antiplatelet drugs, ticagrelor has a binding site different from ADP, making it an allosteric antagonist, and the blockage is reversible. Moreover, the drug does not need hepatic activation, which might work better for patients with genetic variants regarding the enzyme CYP2C19 (although it is not certain whether clopidogrel is significantly influenced by such variants).

TargetActionsOrganism
AP2Y purinoceptor 12
inhibitor
Human
Absorption

Absorbed quickly from the gut, the bioavailability being 36%.

Volume of distribution

The steady state volume of distribution of ticagrelor is 88 L.

Protein binding

Both ticagrelor and AR-C124910XX are bound to plasma proteins (>99.7%), and both are pharmacologically active.

Metabolism

The main metabolite, AR-C124910XX, is formed quickly via CYP3A4 by de-hydroxyethylation at position 5 of the cyclopentane ring. The metabolite reaches 30–40% of ticagrelor's plasma concentrations.

Route of elimination

The primary route of ticagrelor elimination is hepatic metabolism. When radiolabeled ticagrelor is administered, the mean recovery of radioactivity is approximately 84% (58% in feces, 26% in urine).

Half life

Ticagrelor has a half life of 7 hours, while its active metabolite has a half life of 9 hours.

Clearance
Not Available
Toxicity

Bleeding is the expected pharmacologic effect of overdosing. If bleeding occurs, appropriate supportive measures should be taken. Other effects of overdose may include gastrointestinal effects (nausea, vomiting, diarrhea) or ventricular pauses.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabTicagrelor may increase the anticoagulant activities of Abciximab.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Ticagrelor.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Ticagrelor.Approved, Investigational
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Ticagrelor.Approved
Acetyl sulfisoxazoleThe metabolism of Ticagrelor can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the antiplatelet activities of Ticagrelor.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Ticagrelor.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Ticagrelor.Approved, Withdrawn
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Ticagrelor.Experimental
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Ticagrelor.Approved, Illicit, Investigational
AlprostadilAlprostadil may increase the anticoagulant activities of Ticagrelor.Approved, Investigational
AlteplaseTicagrelor may increase the anticoagulant activities of Alteplase.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Ticagrelor.Approved, Withdrawn
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Ticagrelor.Approved
AmiodaroneThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Amiodarone resulting in a loss in efficacy.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Ticagrelor.Approved
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Ticagrelor.Approved, Investigational
AnagrelideAnagrelide may increase the anticoagulant activities of Ticagrelor.Approved
AncrodTicagrelor may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Ticagrelor.Investigational
AnistreplaseTicagrelor may increase the anticoagulant activities of Anistreplase.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Ticagrelor.Approved, Investigational
Antithrombin III humanTicagrelor may increase the anticoagulant activities of Antithrombin III human.Approved
ApalutamideThe serum concentration of Ticagrelor can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Apixaban.Approved
AprepitantThe serum concentration of Ticagrelor can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe therapeutic efficacy of Ticagrelor can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Ticagrelor.Experimental
ArdeparinTicagrelor may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Ticagrelor.Approved, Investigational
ArgatrobanTicagrelor may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Ticagrelor.Approved
AstaxanthinTicagrelor may increase the anticoagulant activities of Astaxanthin.Investigational
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Ticagrelor.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Atazanavir resulting in a loss in efficacy.Approved, Investigational
AtomoxetineThe metabolism of Ticagrelor can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Ticagrelor.Approved
AvatrombopagThe metabolism of Avatrombopag can be decreased when combined with Ticagrelor.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Ticagrelor.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ticagrelor.Approved, Investigational
BatroxobinTicagrelor may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminTicagrelor may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinTicagrelor may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BeraprostBeraprost may increase the anticoagulant activities of Ticagrelor.Investigational
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Ticagrelor.Approved, Investigational
BioallethrinThe metabolism of Bioallethrin can be decreased when combined with Ticagrelor.Approved, Experimental
BivalirudinTicagrelor may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Boceprevir resulting in a loss in efficacy.Approved, Withdrawn
BortezomibThe metabolism of Ticagrelor can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Ticagrelor.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ticagrelor.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ticagrelor.Approved, Investigational
BrigatinibThe serum concentration of Ticagrelor can be decreased when it is combined with Brigatinib.Approved, Investigational
BrinaseTicagrelor may increase the anticoagulant activities of Brinase.Experimental
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Ticagrelor.Approved, Investigational
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ticagrelor.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Ticagrelor.Approved
BuflomedilBuflomedil may increase the anticoagulant activities of Ticagrelor.Experimental
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Ticagrelor.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Ticagrelor.Approved
ButylphthalideButylphthalide may increase the anticoagulant activities of Ticagrelor.Investigational
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ticagrelor.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Ticagrelor.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Ticagrelor.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Ticagrelor.Experimental
Candesartan cilexetilThe metabolism of Candesartan cilexetil can be decreased when combined with Ticagrelor.Approved
CangrelorCangrelor may increase the anticoagulant activities of Ticagrelor.Approved
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Ticagrelor.Approved, Investigational
CaplacizumabTicagrelor may increase the anticoagulant activities of Caplacizumab.Investigational
CarbamazepineThe serum concentration of Ticagrelor can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Carbaspirin calcium.Experimental, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Ticagrelor.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Ticagrelor.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Ticagrelor.Approved, Investigational
CeritinibThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Ceritinib resulting in a loss in efficacy.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ticagrelor.Approved, Withdrawn
CertoparinTicagrelor may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Ticagrelor.Approved, Investigational
CilostazolCilostazol may increase the anticoagulant activities of Ticagrelor.Approved, Investigational
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Ticagrelor.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Ticagrelor.Approved, Investigational, Withdrawn
Citric AcidTicagrelor may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Clarithromycin resulting in a loss in efficacy.Approved
ClemastineThe metabolism of Ticagrelor can be decreased when combined with Clemastine.Approved, Investigational
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Ticagrelor.Approved
CloricromenCloricromen may increase the anticoagulant activities of Ticagrelor.Experimental
ClorindioneTicagrelor may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Ticagrelor can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Ticagrelor.Approved
CobicistatThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Cobicistat resulting in a loss in efficacy.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Ticagrelor.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Collagenase clostridium histolyticum.Approved, Investigational
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Ticagrelor.Approved, Investigational
CrizotinibThe metabolism of Ticagrelor can be decreased when combined with Crizotinib.Approved
CurcuminThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Curcumin resulting in a loss in efficacy.Approved, Investigational
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Ticagrelor.Approved, Investigational
CyclosporineThe serum concentration of Ticagrelor can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateTicagrelor may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Ticagrelor can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalteparinTicagrelor may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTicagrelor may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Ticagrelor.Approved
DapsoneThe metabolism of Dapsone can be decreased when combined with Ticagrelor.Approved, Investigational
DarexabanTicagrelor may increase the anticoagulant activities of Darexaban.Investigational
DarunavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Darunavir resulting in a loss in efficacy.Approved
DasatinibThe serum concentration of Ticagrelor can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Ticagrelor can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Ticagrelor.Approved, Investigational
DelavirdineThe metabolism of Ticagrelor can be decreased when combined with Delavirdine.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Ticagrelor.Investigational
DesirudinTicagrelor may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseTicagrelor may increase the anticoagulant activities of Desmoteplase.Investigational
DexamethasoneThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Dexamethasone resulting in a loss in efficacy.Approved, Investigational, Vet Approved
DextranTicagrelor may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Ticagrelor.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Ticagrelor.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Ticagrelor.Approved, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Ticagrelor.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ticagrelor.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ticagrelor.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ticagrelor.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ticagrelor.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Ticagrelor.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ticagrelor.Approved, Investigational
DiltiazemThe metabolism of Ticagrelor can be decreased when combined with Diltiazem.Approved, Investigational
DiphenadioneTicagrelor may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Ticagrelor.Approved, Investigational
DipyridamoleDipyridamole may increase the anticoagulant activities of Ticagrelor.Approved
DitazoleTicagrelor may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DoconexentThe metabolism of Doconexent can be decreased when combined with Ticagrelor.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Ticagrelor.Approved, Investigational
DonepezilThe metabolism of Donepezil can be decreased when combined with Ticagrelor.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Ticagrelor.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Ticagrelor.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Ticagrelor.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ticagrelor.Approved, Investigational
DoxycyclineThe metabolism of Ticagrelor can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Ticagrelor.Approved, Illicit
DronedaroneThe metabolism of Ticagrelor can be decreased when combined with Dronedarone.Approved
Drotrecogin alfaTicagrelor may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidTicagrelor may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Ticagrelor.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Ticagrelor.Approved, Investigational
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Ticagrelor.Approved, Investigational
EnoxaparinTicagrelor may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Ticagrelor can be decreased when it is combined with Enzalutamide.Approved
EpinastineEpinastine may increase the anticoagulant activities of Ticagrelor.Approved, Investigational
EplivanserinEplivanserin may increase the anticoagulant activities of Ticagrelor.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Ticagrelor.Investigational
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Ticagrelor.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Ticagrelor.Approved, Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ticagrelor.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Ticagrelor.Approved
ErythromycinThe metabolism of Ticagrelor can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EstradiolThe metabolism of Estradiol can be decreased when combined with Ticagrelor.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Ticagrelor.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Ticagrelor.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Ticagrelor.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Ticagrelor.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Ticagrelor.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Ticagrelor.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Ticagrelor.Approved, Investigational
Ethyl biscoumacetateTicagrelor may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe metabolism of Etodolac can be decreased when combined with Ticagrelor.Approved, Investigational, Vet Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Ticagrelor.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Ticagrelor.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ticagrelor.Approved
Ferulic acidTicagrelor may increase the anticoagulant activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ticagrelor.Approved
FibrinolysinTicagrelor may increase the anticoagulant activities of Fibrinolysin.Investigational
FluconazoleThe metabolism of Ticagrelor can be decreased when combined with Fluconazole.Approved, Investigational
FluindioneTicagrelor may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Ticagrelor.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Ticagrelor.Approved, Illicit
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Ticagrelor.Approved, Vet Approved
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Ticagrelor.Approved, Investigational
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Ticagrelor.Approved
FluvoxamineThe metabolism of Ticagrelor can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxTicagrelor may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumTicagrelor may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Ticagrelor.Approved, Investigational
FosamprenavirThe metabolism of Ticagrelor can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ticagrelor can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Ticagrelor can be decreased when it is combined with Fosphenytoin.Approved, Investigational
Fusidic AcidThe serum concentration of Ticagrelor can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabexateTicagrelor may increase the anticoagulant activities of Gabexate.Investigational
GavestinelThe metabolism of Gavestinel can be decreased when combined with Ticagrelor.Investigational
GliclazideThe metabolism of Gliclazide can be decreased when combined with Ticagrelor.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Ticagrelor.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Ticagrelor.Approved, Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Ticagrelor.Approved, Investigational
GlyburideThe metabolism of Glyburide can be decreased when combined with Ticagrelor.Approved
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Ticagrelor.Experimental
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Ticagrelor.Approved, Investigational
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Ticagrelor.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Ticagrelor.Approved, Vet Approved
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Ticagrelor.Experimental
HeparinTicagrelor may increase the anticoagulant activities of Heparin.Approved, Investigational
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Ticagrelor.Approved
HigenamineTicagrelor may increase the anticoagulant activities of Higenamine.Investigational
HistamineThe metabolism of Histamine can be decreased when combined with Ticagrelor.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Ticagrelor.Approved, Illicit
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Ticagrelor.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Ticagrelor.Approved
IbudilastIbudilast may increase the anticoagulant activities of Ticagrelor.Approved, Investigational
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Ticagrelor.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Ticagrelor.Approved, Investigational, Nutraceutical
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Ticagrelor.Approved
IdelalisibThe serum concentration of Ticagrelor can be increased when it is combined with Idelalisib.Approved
IdraparinuxTicagrelor may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Ticagrelor.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Ticagrelor.Investigational
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Ticagrelor.Approved
IloprostIloprost may increase the anticoagulant activities of Ticagrelor.Approved, Investigational
ImatinibThe metabolism of Ticagrelor can be decreased when combined with Imatinib.Approved
IndinavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Indinavir resulting in a loss in efficacy.Approved
IndisulamThe metabolism of Indisulam can be decreased when combined with Ticagrelor.Investigational
IndobufenIndobufen may increase the anticoagulant activities of Ticagrelor.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Ticagrelor.Approved, Investigational
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Ticagrelor.Approved, Investigational
IsavuconazoleThe serum concentration of Ticagrelor can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Ticagrelor can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Ticagrelor can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Itraconazole resulting in a loss in efficacy.Approved, Investigational
IvacaftorThe serum concentration of Ticagrelor can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Ticagrelor.Approved, Investigational
KetamineThe metabolism of Ketamine can be decreased when combined with Ticagrelor.Approved, Vet Approved
KetanserinKetanserin may increase the anticoagulant activities of Ticagrelor.Investigational
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Ticagrelor.Approved, Investigational
KetoconazoleThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Ketoconazole resulting in a loss in efficacy.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Ticagrelor.Approved, Vet Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Ticagrelor.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Ticagrelor.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Ticagrelor.Approved, Investigational
LepirudinTicagrelor may increase the anticoagulant activities of Lepirudin.Approved
LesinuradThe metabolism of Lesinurad can be decreased when combined with Ticagrelor.Approved, Investigational
LetaxabanTicagrelor may increase the anticoagulant activities of Letaxaban.Investigational
LicofeloneThe metabolism of Licofelone can be decreased when combined with Ticagrelor.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Ticagrelor.Approved, Vet Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Ticagrelor.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Ticagrelor.Experimental
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Ticagrelor.Approved, Investigational
LopinavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Lopinavir resulting in a loss in efficacy.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Ticagrelor.Approved, Investigational
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Ticagrelor.Approved, Investigational
LorpiprazoleThe serum concentration of Ticagrelor can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Ticagrelor.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Ticagrelor.Approved, Investigational
LuliconazoleThe serum concentration of Ticagrelor can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ticagrelor can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Ticagrelor.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Ticagrelor.Illicit, Investigational, Withdrawn
Medical CannabisThe metabolism of Medical Cannabis can be decreased when combined with Ticagrelor.Experimental, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Ticagrelor.Approved
MelagatranTicagrelor may increase the anticoagulant activities of Melagatran.Experimental
MelatoninThe metabolism of Melatonin can be decreased when combined with Ticagrelor.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Ticagrelor.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Ticagrelor.Investigational, Withdrawn
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ticagrelor.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Ticagrelor.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Ticagrelor.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Ticagrelor.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Ticagrelor.Approved, Investigational, Vet Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Methyl salicylate.Approved, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ticagrelor.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Ticagrelor.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Ticagrelor.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Ticagrelor.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Ticagrelor.Experimental
MifepristoneThe serum concentration of Ticagrelor can be increased when it is combined with Mifepristone.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Ticagrelor.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Ticagrelor.Approved
MitotaneThe serum concentration of Ticagrelor can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Ticagrelor.Approved, Investigational
MontelukastThe metabolism of Montelukast can be decreased when combined with Ticagrelor.Approved
NabiximolsThe metabolism of Nabiximols can be decreased when combined with Ticagrelor.Approved, Investigational
NadroparinTicagrelor may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatTicagrelor may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilNaftopidil may increase the anticoagulant activities of Ticagrelor.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ticagrelor.Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Ticagrelor.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Ticagrelor.Approved, Investigational
NefazodoneThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Nefazodone resulting in a loss in efficacy.Approved, Withdrawn
NelfinavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Nelfinavir resulting in a loss in efficacy.Approved
NetupitantThe serum concentration of Ticagrelor can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Ticagrelor can be decreased when it is combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Ticagrelor.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Ticagrelor.Approved, Investigational, Vet Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Ticagrelor.Approved
NilotinibThe metabolism of Ticagrelor can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the anticoagulant activities of Ticagrelor.Approved, Investigational, Withdrawn
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ticagrelor.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ticagrelor.Investigational
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Ticagrelor.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Obinutuzumab.Approved, Investigational
OlaparibThe metabolism of Ticagrelor can be decreased when combined with Olaparib.Approved
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Ticagrelor.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ticagrelor.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Ticagrelor.Approved, Nutraceutical
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Ticagrelor.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Ticagrelor.Approved
OsimertinibThe serum concentration of Ticagrelor can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Ticagrelor.Approved, Investigational
OtamixabanTicagrelor may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Ticagrelor.Approved
OzagrelTicagrelor may increase the anticoagulant activities of Ozagrel.Investigational
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Ticagrelor.Approved, Vet Approved
PalbociclibThe serum concentration of Ticagrelor can be increased when it is combined with Palbociclib.Approved, Investigational
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Ticagrelor.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Ticagrelor.Approved
ParnaparinTicagrelor may increase the anticoagulant activities of Parnaparin.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ticagrelor.Approved
Pentaerythritol TetranitrateTicagrelor may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentobarbitalThe serum concentration of Ticagrelor can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ticagrelor.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Ticagrelor.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Ticagrelor.Approved, Investigational, Vet Approved, Withdrawn
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Ticagrelor.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Ticagrelor.Withdrawn
PhenindioneTicagrelor may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe serum concentration of Ticagrelor can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Ticagrelor.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Phenyl aminosalicylate.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Ticagrelor.Approved, Vet Approved
PhenytoinThe serum concentration of Ticagrelor can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Ticagrelor.Experimental
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Ticagrelor.Approved, Investigational
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Ticagrelor.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Ticagrelor.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ticagrelor.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Ticagrelor.Approved, Investigational
PosaconazoleThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Posaconazole resulting in a loss in efficacy.Approved, Investigational, Vet Approved
Potassium CitrateTicagrelor may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Ticagrelor.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Ticagrelor.Approved
PrimidoneThe serum concentration of Ticagrelor can be decreased when it is combined with Primidone.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Ticagrelor.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Ticagrelor.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Ticagrelor.Approved, Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Ticagrelor.Approved, Investigational, Vet Approved
Protein CTicagrelor may increase the anticoagulant activities of Protein C.Approved
Protein S humanTicagrelor may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTicagrelor may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Ticagrelor.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Ticagrelor.Approved, Illicit
QuinidineThe metabolism of Quinidine can be decreased when combined with Ticagrelor.Approved, Investigational
QuinineThe metabolism of Quinine can be decreased when combined with Ticagrelor.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Ticagrelor.Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Ticagrelor.Approved, Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Ticagrelor.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Ticagrelor.Approved, Experimental, Investigational
ReteplaseTicagrelor may increase the anticoagulant activities of Reteplase.Approved, Investigational
ReviparinTicagrelor may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibociclibThe serum concentration of Ticagrelor can be increased when it is combined with Ribociclib.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Ticagrelor.Approved
RifabutinThe serum concentration of Ticagrelor can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Ticagrelor can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Ticagrelor can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Ticagrelor.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Ticagrelor.Approved
RivaroxabanTicagrelor may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Ticagrelor.Approved, Investigational, Withdrawn
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Ticagrelor.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Ticagrelor.Approved
RucaparibThe metabolism of Ticagrelor can be decreased when combined with Rucaparib.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Ticagrelor.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Salicylic acid.Approved, Investigational, Vet Approved
SaquinavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Saquinavir resulting in a loss in efficacy.Approved, Investigational
SarilumabThe therapeutic efficacy of Ticagrelor can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateSarpogrelate may increase the anticoagulant activities of Ticagrelor.Investigational
SaruplaseTicagrelor may increase the anticoagulant activities of Saruplase.Experimental
SelegilineThe metabolism of Selegiline can be decreased when combined with Ticagrelor.Approved, Investigational, Vet Approved
SelexipagTicagrelor may increase the anticoagulant activities of Selexipag.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Ticagrelor.Approved
SertralineThe metabolism of Sertraline can be decreased when combined with Ticagrelor.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Ticagrelor.Approved, Vet Approved
SildenafilThe metabolism of Ticagrelor can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ticagrelor.Approved
SiltuximabThe serum concentration of Ticagrelor can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Ticagrelor can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ticagrelor.Approved
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Ticagrelor.Approved, Investigational, Withdrawn
Sodium CitrateTicagrelor may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
SRT501SRT501 may increase the anticoagulant activities of Ticagrelor.Investigational
St. John's WortThe serum concentration of Ticagrelor can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Stiripentol resulting in a loss in efficacy.Approved
StreptokinaseTicagrelor may increase the anticoagulant activities of Streptokinase.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Ticagrelor.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Ticagrelor.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Ticagrelor.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Ticagrelor.Approved
SulfisoxazoleThe metabolism of Ticagrelor can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideTicagrelor may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenThe metabolism of Suprofen can be decreased when combined with Ticagrelor.Approved, Withdrawn
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Ticagrelor.Approved
TapentadolThe metabolism of Tapentadol can be decreased when combined with Ticagrelor.Approved
TelaprevirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Telaprevir resulting in a loss in efficacy.Approved, Withdrawn
TelithromycinThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Telithromycin resulting in a loss in efficacy.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Ticagrelor.Approved, Investigational
TenecteplaseTicagrelor may increase the anticoagulant activities of Tenecteplase.Approved
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Ticagrelor.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Ticagrelor.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Ticagrelor.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Ticagrelor.Experimental
TesmilifeneTesmilifene may increase the anticoagulant activities of Ticagrelor.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Ticagrelor.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Ticagrelor.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Ticagrelor.Approved
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Ticagrelor.Approved, Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Ticagrelor.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Ticagrelor.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Ticagrelor.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Ticagrelor.Approved, Withdrawn
TiclopidineThe metabolism of Ticagrelor can be decreased when combined with Ticlopidine.Approved
TinzaparinTicagrelor may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolTicagrelor may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Ticagrelor.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Ticagrelor.Approved
TocilizumabThe serum concentration of Ticagrelor can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Ticagrelor.Approved, Investigational
TolterodineThe metabolism of Tolterodine can be decreased when combined with Ticagrelor.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Ticagrelor.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Ticagrelor.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Ticagrelor.Approved
TositumomabThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Tositumomab.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Ticagrelor.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Ticagrelor.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Ticagrelor.Approved
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Ticagrelor.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Ticagrelor.Approved, Investigational, Nutraceutical
TriflusalTriflusal may increase the anticoagulant activities of Ticagrelor.Approved, Investigational
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Ticagrelor.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Ticagrelor.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Ticagrelor.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Ticagrelor.Investigational, Withdrawn
Trolamine salicylateThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Trolamine salicylate.Approved
TroxerutinTicagrelor may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseTicagrelor may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Ticagrelor.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Ticagrelor.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Ticagrelor.Approved, Investigational
VemurafenibThe serum concentration of Ticagrelor can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Ticagrelor can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Ticagrelor can be decreased when combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Ticagrelor.Investigational
VincristineThe excretion of Vincristine can be decreased when combined with Ticagrelor.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Ticagrelor.Approved, Investigational
Vitamin EVitamin E may increase the antiplatelet activities of Ticagrelor.Approved, Nutraceutical, Vet Approved
VorapaxarVorapaxar may increase the anticoagulant activities of Ticagrelor.Approved
VoriconazoleThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Voriconazole resulting in a loss in efficacy.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Ticagrelor.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Ticagrelor.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Ticagrelor.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Ticagrelor.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Ticagrelor.Approved, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Ticagrelor.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Ticagrelor.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Ticagrelor.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Ticagrelor can be decreased when combined with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Ticagrelor.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Ticagrelor.Approved
Food Interactions
Not Available

References

Synthesis Reference

Anil Shahaji Khile, "NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR." U.S. Patent US20130165696, issued June 27, 2013.

US20130165696
General References
  1. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G: Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006 May;27(9):1038-47. Epub 2006 Feb 13. [PubMed:16476694]
  2. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, Cannon CP: Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007 Nov 6;50(19):1852-6. Epub 2007 Oct 23. [PubMed:17980251]
  3. Tantry US, Bliden KP, Gurbel PA: AZD6140. Expert Opin Investig Drugs. 2007 Feb;16(2):225-9. [PubMed:17243942]
  4. Serebruany VL, Stebbing J, Atar D: Dyspnoea after antiplatelet agents: the AZD6140 controversy. Int J Clin Pract. 2007 Mar;61(3):529-33. [PubMed:17313629]
  5. Springthorpe B, Bailey A, Barton P, Birkinshaw TN, Bonnert RV, Brown RC, Chapman D, Dixon J, Guile SD, Humphries RG, Hunt SF, Ince F, Ingall AH, Kirk IP, Leeson PD, Leff P, Lewis RJ, Martin BP, McGinnity DF, Mortimore MP, Paine SW, Pairaudeau G, Patel A, Rigby AJ, Riley RJ, Teobald BJ, Tomlinson W, Webborn PJ, Willis PA: From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett. 2007 Nov 1;17(21):6013-8. Epub 2007 Aug 19. [PubMed:17827008]
  6. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF: Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007 Nov 6;50(19):1844-51. Epub 2007 Oct 23. [PubMed:17980250]
External Links
Human Metabolome Database
HMDB0015702
KEGG Drug
D09017
PubChem Compound
9871419
PubChem Substance
175427101
ChemSpider
8047109
BindingDB
50397205
ChEBI
68558
ChEMBL
CHEMBL398435
PharmGKB
PA165374673
HET
TIQ
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ticagrelor
ATC Codes
B01AC24 — Ticagrelor
AHFS Codes
  • 20:12.18 — Platelet Aggregation Inhibitors
PDB Entries
5alb / 5alc
FDA label
Download (1.21 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingBasic ScienceAortic Valve Stenosis / Inflammatory Reaction / Thrombosis1
1CompletedBasic ScienceAcute Gouty Arthritis / Coronary Artery Disease1
1CompletedBasic ScienceDrug Drug Interactions1
1CompletedBasic ScienceHealthy Volunteers4
1CompletedBasic ScienceImpaired Renal Function1
1CompletedBasic ScienceInhibition on Platelet Aggregation1
1CompletedBasic SciencePharmacokinetics1
1CompletedOtherSickle Cell Disorders1
1CompletedSupportive CareHealthy Volunteers1
1CompletedTreatmentAcute Coronary Syndromes (ACS) / Nonvalvular Atrial Fibrillation1
1CompletedTreatmentAcute Lung Injury (ALI) / Community Acquired Pneumonia (CAP) / Hospital-acquired bacterial pneumonia / Pneumonia1
1CompletedTreatmentBlood Flow Speed / Coronary Flow Velocity1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentKidney Failure,Chronic1
1RecruitingOtherHealthy Volunteers1
1RecruitingOtherSickle Cell Disorders1
1Unknown StatusTreatmentAcute Coronary Syndromes (ACS)1
1, 2RecruitingTreatmentEnd Stage Renal Disease (ESRD) / Vascular Access Patency1
1, 2Unknown StatusScreeningCritical Limb Ischemia (CLI)1
2CompletedNot AvailableCoronary Artery Disease1
2CompletedOtherHealthy Volunteers1
2CompletedPreventionSickle Cell Disorders1
2CompletedTreatmentAbdominal Aortic Aneurysms (AAA)1
2CompletedTreatmentAcute Coronary Syndromes (ACS)4
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Coronary Artery Disease1
2CompletedTreatmentCoronary Artery Disease2
2CompletedTreatmentStable Coronary Artery Disease2
2RecruitingTreatmentAdenosine / Antiplatelet Therapy / Coronary Artery Disease / Platelet Aggregation / Renal Function Abnormal1
2RecruitingTreatmentCarotid Artery Stenosis1
2RecruitingTreatmentCoronary Artery Disease1
2RecruitingTreatmentCritical Illness1
2RecruitingTreatmentStable Angina (SA) / Unstable Angina (UA)1
2TerminatedTreatmentCommunity Acquired Pneumonia, Severe1
2TerminatedTreatmentPeripheral Artery Disease (PAD)1
2Unknown StatusTreatmentST Segment Elevation Myocardial Infarction (STEMI)1
2WithdrawnDiagnosticCardiovascular Disease (CVD)1
2, 3Active Not RecruitingTreatmentAcute Coronary Syndromes (ACS) / Percutaneous Coronary Intervention1
2, 3Active Not RecruitingTreatmentCoronary Artery Disease1
2, 3Active Not RecruitingTreatmentIschemic Attack, Transient / Strokes1
2, 3CompletedTreatmentCoronary Artery Disease1
2, 3RecruitingPreventionCoronary Artery Disease1
2, 3RecruitingTreatmentAcute Coronary Syndromes (ACS)1
2, 3RecruitingTreatmentClopidogrel, Poor Metabolism of / Coronary Artery Disease1
2, 3RecruitingTreatmentPeripheral Arterial Disease (PAD)1
2, 3Unknown StatusTreatmentCLOPIDOGREL, POOR METABOLISM of (Disorder)1
3Active Not RecruitingPreventionType 2 Diabetes Mellitus1
3Active Not RecruitingTreatmentAcute ST Segment Elevation Myocardial Infarction / Thrombolysis in Myocardial Infarction Flow1
3Active Not RecruitingTreatmentCoronary Artery Disease1
3CompletedDiagnosticCoronary Artery Disease / Endothelial Function1
3CompletedHealth Services ResearchPharmacodynamics / Pharmacodynamics of Antiplatelet Agent1
3CompletedPreventionAcute Ischaemic Stroke / Transient Ischaemic Attack (TIA)1
3CompletedPreventionAtherothrombosis / Cardiovascular Mortality / Myocardial Infarction / Strokes1
3CompletedPreventionPeripheral Artery Disease (PAD)1
3CompletedTreatmentAcute Coronary Syndromes (ACS)1
3CompletedTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease1
3CompletedTreatmentAcute Coronary Syndromes (ACS) / Percutaneous Coronary Intervention1
3CompletedTreatmentAcute Coronary Syndromes (ACS) / ST Elevation Myocardial Infarction (STEMI)1
3CompletedTreatmentAcute Myocardial Infarction (AMI)1
3CompletedTreatmentChronic Kidney Disease (CKD)1
3CompletedTreatmentCoronary Artery Disease1
3CompletedTreatmentCoronary Stent Implantation / Platelet Inhibition1
3CompletedTreatmentMyocardial Infarction1
3CompletedTreatmentNonvalvular Atrial Fibrillation / Percutaneous Coronary Intervention1
3CompletedTreatmentPlatelet Reactivity2
3Not Yet RecruitingPreventionAcute Coronary Syndromes (ACS) / Nonvalvular Atrial Fibrillation1
3Not Yet RecruitingTreatmentAcute Coronary Syndromes (ACS)1
3RecruitingPreventionCoronary Artery Disease1
3RecruitingTreatmentAcute Coronary Syndromes (ACS)2
3RecruitingTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease / Stable Angina (SA)2
3RecruitingTreatmentAcute Ischaemic Stroke / Transient Ischaemic Attack (TIA)1
3RecruitingTreatmentCardiovascular Disease (CVD) / Coronary Artery Disease / Myocardial Infarction / Myocardial Ischemia / Stent Thrombosis1
3RecruitingTreatmentCerebral Aneurysms1
3RecruitingTreatmentChronic Kidney Disease (CKD)2
3RecruitingTreatmentMyocardial Infarction / ST Segment Elevation Myocardial Infarction (STEMI)1
3RecruitingTreatmentNonvalvular Atrial Fibrillation1
3RecruitingTreatmentPeripheral Artery Disease (PAD) / Type 2 Diabetes Mellitus1
3TerminatedTreatmentST Segment Elevation Myocardial Infarction (STEMI)1
3Unknown StatusTreatmentNon-ST Segment Elevation Acute Coronary Syndrome1
3WithdrawnBasic ScienceCoronary Heart Disease (CHD)1
4Active Not RecruitingNot AvailableAcute Coronary Syndromes (ACS)1
4Active Not RecruitingSupportive CareCardiovascular Disease (CVD) / Interventional Cardiology1
4Active Not RecruitingTreatmentAcute Coronary Syndromes (ACS) / Angina Pectoris / Cardiovascular Disease (CVD) / Heart Diseases / Myocardial Ischemia1
4Active Not RecruitingTreatmentAntiplatelet Agents / Coronary Artery Bypass Graft1
4Active Not RecruitingTreatmentCoronary Artery Disease1
4Active Not RecruitingTreatmentHeadaches / Migraines / Migrainous Headache1
4Active Not RecruitingTreatmentLOVASTATIN/TICAGRELOR [VA Drug Interaction]1
4Active Not RecruitingTreatmentMyocardial Infarction1
4Active Not RecruitingTreatmentPatients Who Are Scheduled to Undergo a PCI (Percutaneous Coronary Intervention) for CTO (Chronic Total Occlusion)1
4CompletedNot AvailableHealthy Volunteers1
4CompletedBasic ScienceAcute Coronary Syndromes (ACS) / Nonvalvular Atrial Fibrillation1
4CompletedBasic ScienceCoronary Artery Disease1
4CompletedBasic ScienceCoronary Artery Disease / Endothelial Dysfunction / Myocardial Ischemia1
4CompletedPreventionCoronary Artery Disease2
4CompletedSupportive CareAcute Coronary Syndromes (ACS) / Platelet Function1
4CompletedTreatmentAcute Coronary Syndromes (ACS)5
4CompletedTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease1
4CompletedTreatmentAcute Coronary Syndromes (ACS) / ST Elevation Myocardial Infarction1
4CompletedTreatmentAngioplasty, Balloon, Coronary / Myocardial Infarction / Platelet Aggregation Inhibitors1
4CompletedTreatmentAntiplatelet Therapy of Coronary Artery Bypass1
4CompletedTreatmentCardiac Arrest / Postresuscitation Syndrome / ST Elevation (STEMI) and Non-ST Elevation (NSTEMI) Myocardial Infarction1
4CompletedTreatmentCardiovascular Disease (CVD)1
4CompletedTreatmentCoronary Artery Disease6
4CompletedTreatmentCoronary Artery Disease / Diabetes Mellitus (DM)1
4CompletedTreatmentCoronary Artery Disease / Endothelial Function1
4CompletedTreatmentCoronary Artery Disease / Type 2 Diabetes Mellitus1
4CompletedTreatmentCoronary Heart Disease (CHD)1
4CompletedTreatmentFibrinolysis / P2Y12 Inhibitor / ST Elevation Myocardial Infarction1
4CompletedTreatmentFractional Flow Reserve1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentMyocardial Infarction1
4CompletedTreatmentMyocardial Infarction / Segment Elevation Myocardial Infarction (STEMI)1
4CompletedTreatmentNon ST Segment Elevation Acute Coronary Syndrome1
4CompletedTreatmentNon ST Segment Elevation Myocardial Infarction (NSTEMI) / ST Segment Elevation Myocardial Infarction (STEMI)1
4CompletedTreatmentNon ST Segment Elevation Myocardial Infarction (NSTEMI) / ST Segment Elevation Myocardial Infarction (STEMI) / VA Drug Interactions / VA Drug Interactions [VA Drug Interaction]1
4CompletedTreatmentNon-ST or ST Elevation Acute Coronary Syndromes1
4CompletedTreatmentPlaque, Atherosclerotic1
4CompletedTreatmentPlatelet Reactivity1
4CompletedTreatmentST Elevation Myocardial Infarction (STEMI)2
4CompletedTreatmentST Segment Elevation Myocardial Infarction (STEMI)1
4CompletedTreatmentStable Coronary Artery Disease2
4CompletedTreatmentStable Coronary Heart Disease (CHD)1
4CompletedTreatmentThrombosis1
4CompletedTreatmentUnstable Angina Pectoris1
4CompletedTreatmentTransient ischemia attacks2
4Enrolling by InvitationTreatmentChronic Total Occlusion of Coronary Artery / Coronary Artery Disease / Percutaneous Coronary Intervention / Viable Myocardium1
4Enrolling by InvitationTreatmentComplete Occlusion of Coronary Artery / Hibernation, Myocardial1
4Not Yet RecruitingBasic ScienceDiabetes Mellitus (DM)2
4Not Yet RecruitingTreatmentAcute Coronary Syndromes (ACS) / Myocardial Infarction / ST Elevation Myocardial Infarction (STEMI)1
4Not Yet RecruitingTreatmentAcute Myocardial Infarction (AMI) / Shock, Cardiogenic1
4Not Yet RecruitingTreatmentInflammatory Reaction / Thrombosis1
4Not Yet RecruitingTreatmentMicrovascular Angina1
4RecruitingNot AvailableAcute Coronary Syndromes (ACS)1
4RecruitingBasic ScienceMyocardial Infarction1
4RecruitingBasic ScienceMyocardial Infarction / Platelets Dysfunction / Thrombosis1
4RecruitingPreventionAcute Coronary Syndromes (ACS) / Chronic Kidney Disease (CKD)1
4RecruitingPreventionAtherosclerosis1
4RecruitingPreventionSaphenous Vein Graft Disease1
4RecruitingTreatmentACS - Acute Coronary Syndrome / Cardiopulmonary Arrest With Successful Resuscitation / Hypothermia, Induced1
4RecruitingTreatmentAcute Coronary Syndromes (ACS)2
4RecruitingTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease / Stenosis1
4RecruitingTreatmentAcute Coronary Syndromes (ACS) / High On-treatment Platelet Reactivity (HTPR) / Microvascular Obstruction (MVO) / ST Segment Elevation Myocardial Infarction (STEMI) / Thrombolysis in Myocardial Infarction (TIMI) / Unstable Angina (UA)1
4RecruitingTreatmentAcute Myocardial Infarction (AMI)2
4RecruitingTreatmentAngina Pectoris / Cardiovascular Disease (CVD) / Coronary Artery Disease / Heart Diseases / Infarction / Myocardial Infarction / Systemic Embolism / Thoracic Pain / Thrombosis / Transient ischemia attacks / Vascular Diseases1
4RecruitingTreatmentAntiplatelet Therapy / Percutaneous Coronary Intervention / Stable Coronary Syndrome / Ticagrelor1
4RecruitingTreatmentAtherosclerosis1
4RecruitingTreatmentAtherosclerosis / Coronary Artery Disease / Stents1
4RecruitingTreatmentChronic Kidney Disease (CKD) / Non ST Segment Elevation Acute Coronary Syndrome1
4RecruitingTreatmentCoronary Artery Disease4
4RecruitingTreatmentCoronary Artery Disease / Diabetes Mellitus (DM)1
4RecruitingTreatmentCoronary Artery Disease / Diabetes Mellitus (DM) / Kidney Diseases / Myocardial Infarction2
4RecruitingTreatmentCoronary Artery Disease / Nonvalvular Atrial Fibrillation1
4RecruitingTreatmentCoronary Artery Disease / Type 2 Diabetes Mellitus3
4RecruitingTreatmentCoronary Heart Disease (CHD)1
4RecruitingTreatmentEndothelial Dysfunction / Vascular Inflammation1
4RecruitingTreatmentHeart Attacks1
4RecruitingTreatmentMyocardial Fibrosis1
4RecruitingTreatmentMyocardial Infarction1
4RecruitingTreatmentPercutaneous Coronary Intervention1
4RecruitingTreatmentRheumatoid Arthritis1
4RecruitingTreatmentST Elevation Myocardial Infarction / ST Segment Elevation Myocardial Infarction (STEMI)1
4RecruitingTreatmentUnstable Angina Pectoris2
4TerminatedPreventionMyocardial Injury1
4TerminatedTreatmentNon ST Segment Elevation Acute Coronary Syndrome1
4TerminatedTreatmentNon-ST Elevation Acute Coronary Syndrome1
4TerminatedTreatmentPeripheral Arterial Disease (PAD)1
4Unknown StatusHealth Services ResearchAcute Coronary Syndromes (ACS) / Acute ST Segment Elevation Myocardial Infarction1
4Unknown StatusTreatmentAcute Coronary Syndromes (ACS)3
4Unknown StatusTreatmentAntiplatelet Agents; Endothelial Function; Pleotropic Effects1
4Unknown StatusTreatmentCardiovascular Disease (CVD) / Coronary Artery Disease / Myocardial Infarction / Stable Angina (SA)1
4Unknown StatusTreatmentCoronary Artery Disease1
4Unknown StatusTreatmentCoronary Heart Disease (CHD)1
4Unknown StatusTreatmentCoronary Heart Disease (CHD) / Diabetes Mellitus (DM)1
4Unknown StatusTreatmentMyocardial Infarction / No-Reflow Phenomenon1
4Unknown StatusTreatmentPatients Who Are Hospitalized and Expected to Undergo PCI for Acute Coronary Syndrome, Including Acute Myocardial Infarction and Unstable Angina1
4Unknown StatusTreatmentST Segment Elevation Myocardial Infarction (STEMI)1
4WithdrawnNot AvailableAcute Coronary Syndromes (ACS) / Coronary Artery Disease1
4WithdrawnTreatmentAnkle Brachial Index (0.9 or Less) / Arterial Occlusion Disease / Intermittent Claudication / Peripheral Artery Disease (PAD) / Vascular Diseases1
Not AvailableActive Not RecruitingDiagnosticPlatelet Dysfunction Due to Drugs / Risk Factor, Cardiovascular1
Not AvailableActive Not RecruitingTreatmentAcute Coronary Syndromes (ACS)1
Not AvailableCompletedNot AvailableAPT(Antiplatelet Therapy) / HOTPR(High on Treat Platelet Reactivity) / PRU(Platelet Reactivity Unit)1
Not AvailableCompletedNot AvailableAcute Coronary Syndromes (ACS)2
Not AvailableCompletedNot AvailableAcute Coronary Syndromes (ACS) / Clopidogrel / Haemorrhage / Novel Anti-platelets / Ticagrelor1
Not AvailableCompletedNot AvailableAcute Coronary Syndromes (ACS) / Drug-eluting Stent (DES) / Percutaneous Coronary Intervention1
Not AvailableCompletedNot AvailableCoronary Artery Disease1
Not AvailableCompletedNot AvailableMyocardial Infarction2
Not AvailableCompletedBasic ScienceEndotoxaemia1
Not AvailableCompletedTreatmentAcute Coronary Syndromes (ACS)2
Not AvailableCompletedTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease1
Not AvailableCompletedTreatmentAcute Myocardial Infarction (AMI)1
Not AvailableCompletedTreatmentCoronary Artery Disease2
Not AvailableCompletedTreatmentCoronary Artery Disease / Diabetes Mellitus (DM)1
Not AvailableEnrolling by InvitationPreventionCardiovascular Disease (CVD)1
Not AvailableEnrolling by InvitationTreatmentPeripheral Artery Disease (PAD)1
Not AvailableRecruitingNot AvailableACS (Acute Coronary Syndrome) / Patients Alredy on Ticagrelor 2-3 Months Prior to Study Start1
Not AvailableRecruitingNot AvailableAcute Coronary Syndromes (ACS)1
Not AvailableRecruitingNot AvailableAcute Myocardial Infarction (AMI)1
Not AvailableRecruitingNot AvailableCoronary Artery Disease1
Not AvailableRecruitingNot AvailablePlatelet Aggregation Onhibitors1
Not AvailableRecruitingTreatmentAspirin / Platelet Dysfunction Due to Drugs / Ticagrelor / Transfusions1
Not AvailableRecruitingTreatmentST Elevation Myocardial Infarction1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral60 mg/1
TabletOral60 mg
TabletOral90 mg/1
TabletOral90 mg
Tablet, film coatedOral60 mg
Tablet, film coatedOral90 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2296665No2008-06-102018-07-15Canada
CA2351709No2010-04-062019-12-02Canada
CA2408596No2010-12-212021-05-31Canada
US7265124No2001-07-092021-07-09Us
US6525060No1999-12-022019-12-02Us
US7250419No1999-12-022019-12-02Us
US6251910No1998-07-152018-07-15Us
US8425934No2010-04-172030-04-17Us
USRE46276No1999-12-022019-12-02Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility10 μg/mLFDA Label
Predicted Properties
PropertyValueSource
Water Solubility0.063 mg/mLALOGPS
logP2.31ALOGPS
logP2.28ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.94ChemAxon
pKa (Strongest Basic)2.93ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area138.44 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity142.13 m3·mol-1ChemAxon
Polarizability51.27 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.994
Blood Brain Barrier-0.6719
Caco-2 permeable-0.5989
P-glycoprotein substrateSubstrate0.7626
P-glycoprotein inhibitor INon-inhibitor0.5907
P-glycoprotein inhibitor IINon-inhibitor0.9617
Renal organic cation transporterNon-inhibitor0.8606
CYP450 2C9 substrateNon-substrate0.7734
CYP450 2D6 substrateNon-substrate0.8048
CYP450 3A4 substrateSubstrate0.5057
CYP450 1A2 substrateNon-inhibitor0.5372
CYP450 2C9 inhibitorNon-inhibitor0.5767
CYP450 2D6 inhibitorNon-inhibitor0.8016
CYP450 2C19 inhibitorNon-inhibitor0.6016
CYP450 3A4 inhibitorInhibitor0.8744
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6243
Ames testNon AMES toxic0.5075
CarcinogenicityNon-carcinogens0.7777
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6308 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7742
hERG inhibition (predictor II)Non-inhibitor0.5914
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as triazolopyrimidines. These are polycyclic aromatic compounds containing triazole ring fused to a pyrimidine ring. Triazole is a five-membered ring consisting of two carbon atoms and three nitrogen atoms. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Triazolopyrimidines
Sub Class
Not Available
Direct Parent
Triazolopyrimidines
Alternative Parents
Alkylarylthioethers / Aminopyrimidines and derivatives / Secondary alkylarylamines / Fluorobenzenes / Aryl fluorides / Cyclitols and derivatives / Cyclopentanols / Imidolactams / Triazoles / Heteroaromatic compounds
show 7 more
Substituents
Triazolopyrimidine / Aryl thioether / Aminopyrimidine / Fluorobenzene / Halobenzene / Secondary aliphatic/aromatic amine / Alkylarylthioether / Cyclitol or derivatives / Aryl fluoride / Aryl halide
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organofluorine compound, aryl sulfide, secondary amino compound, triazolopyrimidines, hydroxyether (CHEBI:68558)

Targets

Details
1. P2Y purinoceptor 12
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation.
Gene Name
P2RY12
Uniprot ID
Q9H244
Uniprot Name
P2Y purinoceptor 12
Molecular Weight
39438.355 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Teng R, Oliver S, Hayes MA, Butler K: Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010 Sep;38(9):1514-21. doi: 10.1124/dmd.110.032250. Epub 2010 Jun 15. [PubMed:20551239]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da

Drug created on August 01, 2011 15:32 / Updated on June 24, 2018 11:36